Stay updated on Nivolumab With Azacitidine in AML Clinical Trial
Sign up to get notified when there's something new on the Nivolumab With Azacitidine in AML Clinical Trial page.

Latest updates to the Nivolumab With Azacitidine in AML Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedLocations section now includes Texas; the old label 'Texas Locations' has been removed. Updated the footer to revision v3.3.3 and removed the 'HHS Vulnerability Disclosure' line.SummaryDifference0.2%

- Check46 days agoChange DetectedRevision: v3.3.2 replaces v3.3.1 on the page. This appears to be an administrative version update with no visible changes to the study details.SummaryDifference0.0%

- Check53 days agoChange DetectedPublications section updated to clarify that entries are automatically filled from PubMed, and the page template revision is noted (additions: v3.3.1; deletions: v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check61 days agoChange DetectedFunding-status notice about lapses in government funding has been removed from the page, reducing visibility of site-wide operating status for users viewing this study record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check75 days agoChange DetectedNo significant changes to core study content, design, arms, outcomes, or eligibility criteria were detected; observed differences are limited to minor text formatting and an updated last-modified timestamp. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Nivolumab With Azacitidine in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab With Azacitidine in AML Clinical Trial page.